Protagonist Therapeutics, Inc
https://www.polycythemiavera-clinicaltrial.com/
Protagonist Therapeutics, Inc. is a biopharmaceutical company with peptide-based new chemical entities, rusfertide and PN-235, in different stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate. VERIFY, the global phase 3 registrational study of rusfertide in polycythemia vera, is currently underway and is enrolling patients throughout the world.